About the Company

AzurRx BioPharma (NasdaqGM: AZRX) is a biopharmaceutical company focused on the development of oral recombinant products to address gastrointestinal diseases and microbiome related conditions. The Company’s lead candidate, MS1819, is a recombinant yeast lipase that is being developed for the treatment of exocrine pancreatic insufficiency (EPI). This occurs when there is a lack of pancreatic digestive enzymes necessary for nutrient digestion and absorption. There are numerous causes for EPI, including chronic pancreatitis (CP) and cystic fibrosis (CF). MS1819 is currently in a Phase IIa study in patients with EPI caused by CP. Topline results from the trial are expected in the first half of 2017. In addition, the initiation of a Phase IIb crossover trial is anticipated in the first half of 2017. The Company is also developing is AZX1101, a beta-lactamase that is currently in preclinical testing for preventing hospital acquired infections and antibiotic associated diarrhea in patients receiving intravenous beta-lactam antibiotics.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research